StreetInsider.com News Articles

Form 8-K iBio, Inc. For: Jul 17

Fri, 17 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260717/26784417.html

Form 8-K iBio, Inc. For: Jul 17

Fri, 17 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260717/26784417.html

Form 8-K iBio, Inc. For: Jul 01

Wed, 01 Jul 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260701/26716850.html

Form 8-K iBio, Inc. For: Jul 01

Wed, 01 Jul 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260701/26716850.html

iBio reports preclinical data on IBIO-610 Activin E antibody in obese NHPs

Wed, 01 Jul 2026 07:02:23 -0400

iBio, Inc. (NASDAQ: IBIO) announced preclinical data from an obese non-human primate study evaluating IBIO-610, an Activin E antibody candidate, according to a press release from the clinical-stage biotechnology company.

In the study, a single dose of IBIO-610 reduced active Activin E levels in all treated animals through eight weeks. Active Activin E was reduced by 98% at week four and 97% at week eight compared with baseline, with levels falling below the limits of the assay at both time points.

In obese non-human primates receiving IBIO-610 in combination with semaglutide, the combination produced greater visceral and total fat loss while reducing

iBio reports preclinical data on IBIO-610 Activin E antibody in obese NHPs

Wed, 01 Jul 2026 07:02:23 -0400

In obese non-human primates receiving IBIO-610 in combination with semaglutide, the combination produced greater visceral and total fat loss while reducing

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Wed, 01 Jul 2026 07:00:00 -0400

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach

When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone

Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting

SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced new preclinical data from its

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Wed, 01 Jul 2026 07:00:00 -0400

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach

When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone

Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Wed, 01 Jul 2026 07:00:00 -0400

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach

When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone

Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Wed, 01 Jul 2026 07:00:00 -0400

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach

When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone

Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting

Raymond James Starts iBio, Inc. (IBIO) at Outperform

Mon, 08 Jun 2026 06:07:12 -0400

Raymond James analyst Martin Auster initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Outperform rating and a price target of $5.00.

The analyst comments "We initiate coverage of iBio (IBIO) with an Outperform rating and $5 target price. IBio using its proprietary AI-integrated platform to is developing next-generation antibody therapies for challenging targets; its first antibody (IBIO-600, myostatin) recently entered the clinic with two more INDs expected in the next 12 months. We see a compelling valuation and an excellent riskreward for investors as the company’s diverse set of potentially differentiated assets approach PoC in areas of high unmet need

Raymond James Starts iBio, Inc. (IBIO) at Outperform

Mon, 08 Jun 2026 06:07:12 -0400

Raymond James analyst Martin Auster initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Outperform rating and a price target of $5.00.

Raymond James Starts iBio, Inc. (IBIO) at Outperform

Mon, 08 Jun 2026 06:07:12 -0400

Raymond James analyst Martin Auster initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Outperform rating and a price target of $5.00.

Raymond James Starts iBio, Inc. (IBIO) at Outperform

Mon, 08 Jun 2026 06:07:12 -0400

Raymond James analyst Martin Auster initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Outperform rating and a price target of $5.00.

B.Riley Starts iBio, Inc. (IBIO) at Buy

Fri, 05 Jun 2026 08:36:04 -0400

B.Riley analyst William Wood initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Buy rating and a price target of $6.00.

For an analyst ratings summary and ratings history on iBio, Inc. click here. For more ratings news on iBio, Inc. click here.

Shares of iBio, Inc. closed at $1.93 yesterday.

iBio to Participate in Upcoming Healthcare Investor Conferences

Tue, 02 Jun 2026 16:01:00 -0400

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference.

Jefferies Global Healthcare Conference
Presentation Date: Thursday, June 4, 2026
Time: 11:40 a.m. ET
Location: Marriott Marquis, New York

A livestream of the event can be accessed link,

iBio to Participate in Upcoming Healthcare Investor Conferences

Tue, 02 Jun 2026 16:01:00 -0400

Jefferies Global Healthcare Conference
Presentation Date: Thursday, June 4, 2026
Time: 11:40 a.m. ET
Location: Marriott Marquis, New York

A livestream of the event can be accessed link,

iBio begins phase 1 trial of obesity drug IBIO-600

Tue, 02 Jun 2026 07:00:29 -0400

iBio Inc. (NASDAQ: IBIO) announced it has dosed the first participant in a Phase 1 clinical trial of IBIO-600, an investigational treatment for adults with obesity. The milestone marks the company's transition to clinical-stage status.

IBIO-600 is a long-acting monoclonal antibody designed to target myostatin and GDF11, which are negative regulators of skeletal muscle growth. The therapy is being developed to support muscle preservation and improve body composition during weight reduction, including potential use with GLP-1-based therapies.

In non-human primate studies, a single administration of IBIO-600 produced a half-life of 40 to 52 days and demonstrated body composition effects, including lean mass

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

Tue, 02 Jun 2026 07:00:00 -0400

IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition

First-in-human study of IBIO-600 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with obesity

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing of the first participant in its Phase 1 clinical trial of IBIO-600, the Company’s most advanced obesity and cardiometabolic asset and its first program to enter human clinical

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

Tue, 02 Jun 2026 07:00:00 -0400

IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition

First-in-human study of IBIO-600 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with obesity

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

Tue, 02 Jun 2026 07:00:00 -0400

IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition

First-in-human study of IBIO-600 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with obesity

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

Tue, 02 Jun 2026 07:00:00 -0400

IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition

First-in-human study of IBIO-600 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with obesity

Form 4 iBio, Inc. For: May 18 Filed by: Stoner Elizabeth

Tue, 19 May 2026 07:45:00 -0400

si-local-file:///var/storage/secattach/20260519/26517355.html

Form 4 iBio, Inc. For: May 18 Filed by: Stoner Elizabeth

Tue, 19 May 2026 07:45:00 -0400

si-local-file:///var/storage/secattach/20260519/26517355.html

Form SCHEDULE 13G/A iBio, Inc. Filed by: Logos Global Management LP

Fri, 15 May 2026 18:42:00 -0400

si-local-file:///var/storage/secattach/20260515/26508285.html